Please login to the form below

Not currently logged in

Dr Arndt Schottelius to lead Kymab’s R&D

He takes up the newly-created role of executive vice president of R&D

Kymab Dr Arndt SchotteliusCambridge, UK-based Kymab has appointed Dr Arndt Schottelius to the newly-created position of executive vice president of research and development.

Dr Schottelius will take on responsibility for the human monoclonal antibody specialist's R&D activities, including pre-clinical and clinical developments, from May this year.

He joins from MorphoSys, where he has been chief development officer since 2008, overseeing a portfolio of therapeutic antibody programmes in oncology and immunology.

Previously, Dr Schottelius was medical director of immunology development at Genentech based in San Francisco, US, and held scientific and management positions in immunology research at Berlex Biosciences in California, US and Schering AG in Berlin, Germany.

Dr David Chiswell, chief executive of Kymab, said: “I am delighted to welcome Dr Schottelius to the Kymab team.

“His strong management expertise developed at both MorphoSys AG and Genentech as well as his unique experience and track record in drug development supports our commitment to pursue the opportunities in our R&D programmes following our recent $100m Series C funding.

“Dr Schottelius' appointment validates the current strength and exciting potential of our growing product pipeline.”

3rd February 2017

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...